Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1, EVOLVE‐2, and REGAIN Studies

Headache: The Journal of Head and Face Pain Pub Date : 2019-11-13 DOI:10.1111/head.13684

T. Oakes, R. Kovacs, Noah L Rosen, E. Doty, P. Kemmer, S. Aurora, A. Camporeale

引用次数: 26

Abstract

Blood pressure (BP), pulse, electrocardiogram (ECG), and clinical cardiovascular (CV) outcomes in patients with episodic or chronic migraine treated for up to 6 months with galcanezumab compared to placebo were evaluated.

查看原文本刊更多论文

评价Galcanezumab治疗的发作性或慢性偏头痛成年患者的心血管结局:来自三个3期、随机、双盲、安慰剂对照的EVOLVE‐1、EVOLVE‐2和gain研究的数据

与安慰剂相比，用galcanezumab治疗长达6个月的发作性或慢性偏头痛患者的血压(BP)、脉搏、心电图(ECG)和临床心血管(CV)结果进行了评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Headache: The Journal of Head and Face Pain

自引率

0.00%

发文量